AUSTIN, TX, Aug. 14, 2012 /CNW Telbec/ - Akela Pharma, Inc. (“Akela”), (TSX: AKL), an industry leader in providing contract drug formulation development as well as pharmaceutical clinical and commercial manufacturing, today announced its financial results for the three and six months ended June 30, 2012.
Consolidated net revenues for the three months ended June 30, 2012 were $2.8 million, as compared to $3.1 million, for the same period during the previous year. Consolidated revenues for the six months ended June 30, 2012 were $3.7 million as compared to $7.3 million for the same period in 2011.
Consolidated net income (loss) for the three months ended June 30, 2012 was $0.71 million, or $0.02 per share, versus ($0.52) million or ($0.02) per share, for the same period in 2011. Consolidated net income (loss) for the six months ended June 30, 2012 was ($1.45) million vs. $0.48 million, for the same period in 2011.
